<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02969083</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2016-004017-27</org_study_id>
    <nct_id>NCT02969083</nct_id>
  </id_info>
  <brief_title>Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma</brief_title>
  <acronym>URANUS</acronym>
  <official_title>Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial (&quot;URANUS&quot;)&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The European Uro-Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Human Drug Research, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The European Uro-Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to explore feasibility of Upper Tract Urothelial Carcinoma (UTUC)&#xD;
      treatments based in real world data in various European countries. The study will allow to&#xD;
      gain insight in the true proportion of patients that fit to receive complete cisplatin-based&#xD;
      neo-adjuvant or adjuvant chemotherapy, and the proportion and clinical outcome of patients&#xD;
      with poor prognostic factors (PS and renal function) who receive only standard treatment&#xD;
      (Radical nephroureterectomy (RNU)). This comparison will be made using a uniform diagnostic&#xD;
      and treatment protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are no definitive treatment recommendations for patients diagnosed with UTUC. Radical&#xD;
      nephroureterectomy (RNU) has been considered the gold standard treatment for UTUC. However&#xD;
      due to the high recurrence rates reported, patients are often offered perioperative&#xD;
      chemotherapy provided that they have a good renal function and performance status. With&#xD;
      regard to the choice of chemotherapy treatment, there are also no clear recommendations since&#xD;
      there are no data from randomized studies. If perioperative chemotherapy is considered in&#xD;
      daily practice, gemcitabine/cisplatin regimen is often chosen and occasionally dd-MVAC.&#xD;
&#xD;
      The aim of this study is to explore feasibility of UTUC treatments based in real world data&#xD;
      in various European countries. Patients who fulfil good prognostic factors (inclusion&#xD;
      criteria for treatment randomization) will be allocated to neo-adjuvant (Arm B) or adjuvant&#xD;
      (Arm C) chemotherapy (receiving 3 cycles of gemcitabine/cisplatin or dose dense Methotrexate,&#xD;
      Vinblastine, Adriamycin, and Cisplatin (MVAC). Patients who don't fulfil criteria for&#xD;
      treatment randomization will undergo Radical nephroureterectomy (RNU) only (Arm A). Patients&#xD;
      will be followed up for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2018</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of UTUC patients randomized to neo- or adjuvant chemotherapy that is actually able to start and finalize three courses of planned chemotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients randomised to adjuvant or neo-adjuvant treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>1-2 years</time_frame>
    <description>time from randomisation to local recurrence or distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1-2 years</time_frame>
    <description>time from randomisation to death for any cause different from urothelial carcinoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-Specific Survival (CSS)</measure>
    <time_frame>1-2 years</time_frame>
    <description>time from randomisation to death from urothelial carcinoma</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Upper Tract Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radical nephro-ureterectomy (RNU)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who dont fulfil inclusion criteria for chemotherapy treatment randomization (poor renal function: Glomerular Filtration Rate (GFR) &lt;55 ml/min or unfit for cisplatin-based chemotherapy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine/Cisplatin plus RNU</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF &gt; or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RNU plus Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF &gt; or = 55 ml/min) receiving 3 cycles of Gemcitabine (1000 mg/m2) + Cisplatin (70 mg/m2) every 3 weeks after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>M-VAC protocol plus RNU</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF &gt; or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RNU plus M-VAC protocol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who fulfil inclusion criteria for cisplatinum-based chemotherapy (renal function: GRF &gt; or = 55 ml/min) receiving 3 cycles of MVAC every 2 weeks (Methotrexate (30 mg /m²) , Vinblastine (3 mg /m²) , Adriamycin (30 mg /m²) , and Cisplatin (70 mg /m²) after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RNU</intervention_name>
    <description>Radical surgical removal by open or laparoscopic access</description>
    <arm_group_label>Gemcitabine/Cisplatin plus RNU</arm_group_label>
    <arm_group_label>M-VAC protocol plus RNU</arm_group_label>
    <arm_group_label>RNU plus Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_label>RNU plus M-VAC protocol</arm_group_label>
    <arm_group_label>Radical nephro-ureterectomy (RNU)</arm_group_label>
    <other_name>Radical nephro-ureterectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/Cisplatin</intervention_name>
    <description>Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1</description>
    <arm_group_label>Gemcitabine/Cisplatin plus RNU</arm_group_label>
    <arm_group_label>RNU plus Gemcitabine/Cisplatin</arm_group_label>
    <other_name>Gemcitabine plus Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M-VAC Protocol</intervention_name>
    <description>Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2</description>
    <arm_group_label>M-VAC protocol plus RNU</arm_group_label>
    <arm_group_label>RNU plus M-VAC protocol</arm_group_label>
    <other_name>DD MVAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Histological and radiological defined UTUC: Histologically-confirmed diagnosis of&#xD;
             predominantly urothelial carcinoma of the upper urinary tract Patients with UTUC&#xD;
             cT2-pT4 cN0-N1 M0 (TNM classification)&#xD;
&#xD;
          -  Women with negative serum pregnancy test within 14 days of first dose of study&#xD;
             treatment and agreement to use effective contraception&#xD;
&#xD;
          -  Patients without bladder cancer or with concomitant non muscle invasive bladder cancer&#xD;
&#xD;
          -  Adequate organ system function defined as follows: Hematologic: Absolute neutrophil&#xD;
             count (ANC) 1.5 X 109/L; Haemoglobin 5.6 mmol/L (9.02g/dL); Platelets 100 X 109/L;&#xD;
             Prothrombin time (PT) or international normalized ratio (INR)b 1.2 X ULN; Activated&#xD;
             partial thromboplastin time (aPTT)1.2 X Upper limit of normal (ULN). Hepatic: Total&#xD;
             bilirubin 1.5 X ULN; Alanine amino transferase (ALT) and Aspartate aminotransferase&#xD;
             (AST) 2.5 X ULN. Renal: GRF &lt;or&gt; 55 ml/min: Electrolytes: potassium and calcium:&#xD;
             within normal limits.&#xD;
&#xD;
          -  CT scan of the chest, abdomen and pelvis and Bone scan without evidence of distant&#xD;
             metastasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histology of pure adenocarcinoma, pure squamous cell carcinoma, sarcomatoid or&#xD;
             predominant small cell carcinoma.&#xD;
&#xD;
          -  History of cardiovascular conditions within the past 6 months.&#xD;
&#xD;
          -  Incidentally found asymptomatic pulmonary embolism (PE) or recent deep vein thrombosis&#xD;
             (DVT) is not an exclusion criteria but requires anticoagulation treatment.&#xD;
&#xD;
          -  Any major contraindication to a surgical procedure.&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that&#xD;
             could interfere with subject's safety, provision of informed consent, or compliance to&#xD;
             study procedures.&#xD;
&#xD;
          -  Active infection contraindicating chemotherapy&#xD;
&#xD;
          -  Other active neoplasms. Patients with in situ cervical carcinoma, non-melanoma skin&#xD;
             cancer or prostate cancer T1 Gleason &lt;7, Prostate specific antigen (PSA) &lt;10. Patients&#xD;
             with past medical history of cancer can be included if diagnosed at least 4 years ago.&#xD;
&#xD;
          -  Concomitant muscle invasive bladder cancer&#xD;
&#xD;
          -  Patients who have been or still are on methotrexate treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne Osanto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cristina Alvarez, MSc, PhD</last_name>
    <phone>+31(0)715264109</phone>
    <email>m.c.alvarez@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Van der Heijden</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Osanto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne Ziekenhuis</name>
      <address>
        <city>Leiderdorp</city>
        <state>South-Holland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Goossens-Laan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Somford</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Beisland</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Molina</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario German Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Alves</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Puigvert</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Palou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Ribal</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital San Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Maroto</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Morales</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Basurto</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Martin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Doctor Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Comet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez De La Frontera</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Amores</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Complex Insular-Materno Infantil</name>
      <address>
        <city>Las Palmas</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Gómez de Liaño</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Villacampa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Buendia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Burgos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Alvarez-Maestro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Fernandez Aparicio</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Montesino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Gallardo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Gomez Veiga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Campos Juanatey</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Osman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Climent</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Rioja</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2016</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UTUC</keyword>
  <keyword>Upper Tract Urothelial Carcinoma</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>Radical nephroureterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The results obtained in this study will be disseminated and published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

